NCT04740190: TAC-GReD

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Completed Phase 2 Last updated 11 June 2025

What this trial tests

Phase 2 trial testing Talazoparib in Recurrent Glioma in 33 participants. Completed in 14 December 2023.

Timeline

1 January 2021

Primary endpoint
14 December 2023

14 December 2023

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 January 2021
Primary completion	14 December 2023
Estimated completion	14 December 2023
Sites	1 location across Hong Kong

Drugs / interventions tested

• Talazoparib (talazoparib) — full drug profile →

Conditions studied

• Recurrent Glioma — all drugs for Recurrent Glioma →
• Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
• Poly ADP Ribose Polymerase (PARP) Inhibitor — all drugs for Poly ADP Ribose Polymerase (PARP) Inhibitor →
• PTEN Gene Inactivation — all drugs for PTEN Gene Inactivation →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Recurrent Glioma or Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma. Carboplatin will be added to sensitize the tumor to PARP inhibition, and low dose radiation therapy will be applied to increase talazoparib drug penetration through blood-brain barrier. The goal is to estimate the effect size of such combinational treatment approach in recurrent high-grade glioma with DNA damage repair deficiency (dDDR)

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
   Lin H, Liu C, Hu A, Zhang D, et al · · 2024 · cited 232× · PMID 38720342 · DOI 10.1186/s13045-024-01544-7
2. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
   Verdugo E, Puerto I, Medina MÁ. · · 2022 · cited 152× · PMID 36129048 · DOI 10.1002/cac2.12361
3. Glioblastoma Therapy: Past, Present and Future.
   Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, et al · · 2024 · cited 147× · PMID 38473776 · DOI 10.3390/ijms25052529
4. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
   Wang M, Chen S, Ao D. · · 2021 · cited 84× · PMID 34977872 · DOI 10.1002/mco2.103
5. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
   Findlay IJ, De Iuliis GN, Duchatel RJ, Jackson ER, et al · · 2022 · cited 77× · PMID 34759345 · DOI 10.1038/s41388-021-02102-y
6. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.
   Liu H, Qiu W, Sun T, Wang L, et al · · 2022 · cited 58× · PMID 35847506 · DOI 10.1016/j.apsb.2021.12.019
7. PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities.
   Sim HW, Galanis E, Khasraw M. · · 2022 · cited 36× · PMID 35205750 · DOI 10.3390/cancers14041003
8. Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials.
   Sharma N, Mallela AN, Shi DD, Tang LW, et al · · 2023 · cited 27× · PMID 37287696 · DOI 10.1093/noajnl/vdad053